Protara Launches $75 Million Public Offering to Fuel Drug Development
Protara Announces Proposed Public Offering
NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) ("Protara"), a clinical-stage company developing transformative therapies, has launched an underwritten public offering worth up to $75 million. The company plans to sell shares of its common stock or pre-funded warrants to investors. Three major financial firms—J.P. Morgan, TD Cowen, and Piper Sandler—are leading the process as joint book-runners.
The offering will operate under a shelf registration statement on Form S-3, previously filed with the US Securities and Exchange Commission (SEC). A preliminary prospectus supplement and accompanying documents will soon be available on the SEC’s website. Interested investors are advised to review these materials, along with Protara’s other SEC filings, before making any decisions.
The success of the $75 million offering will depend on investor interest and regulatory compliance. If completed, the funds will advance Protara’s drug development pipeline, including its key candidate, TARA-002. Further updates will be available through the SEC’s public filings.
